AUTHORS
Christina Mathilde Verbruggen, PhD, Umair Munawar, PhD2, Patrick Eiring3, Seungbin Han4, Ann-Sophie Hainold5, Emma Besant6, Cornelia Vogt7, Silvia Nerreter8, Shilpa Kurian9, Sven Neubert10, Yoko Tamamushi, MD11, Torsten Steinbrunn, MD, PhD12, Hermann Einsele, MD, PhD13, Markus Sauer14, Johannes Waldschmidt, MD15, K. Martin Kortüm, MD16
AFFILIATIONS
1 University Hospital Wuerzburg, Wuerzburg, Germany
2 University Hospital Wuerzburg, Wuerzburg, Germany
3 University of Wuerzburg, Wuerzburg, Germany
4 University Hospital Wuerzburg, Wuerzburg, Germany
5 University Hospital Wuerzburg, Wuerzburg, Germany
6 University Hospital Wuerzburg, Wuerzburg, Germany
7 University Hospital Wuerzburg, Wuerzburg, Germany
8 University Hospital Wuerzburg, Wuerzburg, Germany
9 University Hospital Wuerzburg, Wuerzburg, Germany
10 University Hospital Wuerzburg, Wuerzburg, Germany
11 University Hospital Wuerzburg, Wuerzburg, Germany
12 University Hospital Wuerzburg, Wuerzburg, Germany
13 University Hospital Wuerzburg, Wuerzburg, Germany
14 University of Wuerzburg, Wuerzburg, Germany
15 University Hospital Wuerzburg, Wuerzburg, Germany
16 University Hospital Wuerzburg, Wuerzburg, Germany
ABSTRACT
Introduction
Immunotherapies have shown exceptional potential in achieving deep and durable remissions in multiple myeloma (MM), but rely on sustained target surface expression for their therapeutic efficacy. Although CD38-directed antibodies are widely used in MM, it remains unclear how repeated treatment influences the availability of surface CD38 for subsequent therapeutic engagement. We applied quantitative super-resolution imaging to investigate CD38 surface accessibility over time under daratumumab (Dara) and isatuximab (Isa) treatment.
Methods
We applied direct Stochastic Optical Reconstruction Microscopy (dSTORM) to map CD38 surface availability in AMO1 (CD38low) and RPMI8226 (CD38high) MM cell lines. Cells were treated on day 0 and day 7 with 10 µg/mL Dara or Isa for 1 hour, a concentration sufficient to saturate accessible CD38 receptors in both cell lines, followed by washing to remove unbound antibody. This standardized treatment ensured comparable receptor occupancy despite differences in baseline CD38 expression. We then performed dSTORM on day 1, day 7 (before retreatment), day 8 and day 14 using a polyclonal CD38 multi-epitope antibody to quantify membrane-accessible CD38. We further used Airyscan confocal microscopy to visualize antibody internalization by treating the cells for 1 to 4h with fluorescently labeled antibodies, complemented by dSTORM 1-hour post-treatment to assess CD38 membrane availability.
Results
dSTORM confirmed rapid depletion of membrane-accessible CD38 following anti-CD38 treatment in both AMO1 and RPMI8226 cell lines. Dara induced a faster reduction in surface-accessible CD38 upon first dose than Isa in both models (day 1, WT vs. Dara vs. Isa: AMO1, 11.8±0.9 vs. 2.0±0.5 vs. 3.6±0.4; RPMI8226, 32.1±3.9 vs. 5.1±0.5 vs. 10.5±1.5 localization clusters/µm²; all p<0.0001). An incomplete CD38 recovery was observed in AMO1 7 days post Dara treatment, however, it was (AMO1, 7.3±0.8 localization clusters/µm², p=0.001) was fully restored in RPMI8226 cells. (28.6±1.7 localization clusters/µm², p=1). Complete C38 recovery was achieved in both cell lines 7 days post Isa treatment (AMO1 11.6±1.5, p=0.66; RPMI8226 31.1±2.0 localization clusters/µm², p=0.68). A second dose, mimicking a weekly clinical dosing schedule, again rapidly reduced membrane-accessible CD38 (day 8, Dara vs. Isa: AMO1, 4.3±0.7, p=0.005 vs. 6.5±0.8, p=0.004; RPMI8226, 12.7±1.8, p<0.0001 vs. 19.4±1.7 localization clusters/µm², p=0.0002). However, depletion was less pronounced compared to the initial treatment, suggesting altered receptor regulation following repeated therapeutic engagement. Importantly, neither Dara nor Isa-treated cells restored baseline CD38 levels by day 14, indicating that weekly treatment maintains reduced target availability. Next, confocal microscopy was employed to track the cellular localization of CD38 after therapeutic antibody exposure. Both Dara and Isa rapidly accumulated intracellularly within 4 hours, suggesting antibody-mediated receptor internalization. Correspondingly, dSTORM confirmed a significant reduction in membrane-accessible CD38 already 1 hour following antibody exposure (AMO1-Dara: 2.2±0.3, p<0.0001; AMO1-Isa: 3.9±1.0, p<0.0001; RPMI8226-Dara: 10.2±1.0, p<0.0001; RPMI8226-Isa: 14.3±1.8 localization clusters/µm², p=0.0002). Together these data support receptor internalization as an important mechanism limiting target availability during repeated anti-CD38 therapy.
Conclusion
Using dSTORM we demonstrate that repeated weekly anti-CD38 treatment suppresses membrane-accessible CD38 through receptor depletion and internalization, providing mechanistic support for the initial weekly dosing schedules used clinically for both Dara and Isa. Dara induced more profound and sustained target loss than Isa, highlighting differences in CD38 regulation following therapeutic engagement. As only two consecutive weekly treatment cycles were investigated, whether longer treatment intervals used during maintenance permit complete receptor recovery remains to be determined.
DISCLOSURES
Christina Mathilde Verbruggen, PhD: No relevant conflicts of interest to declare.